|
KR100785363B1
(ko)
|
2000-04-25 |
2007-12-18 |
이코스 코포레이션 |
인간 포스파티딜-이노시톨 3-키나제 델타의 억제제
|
|
US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
|
GB2405870B
(en)
*
|
2001-08-14 |
2005-07-06 |
Cancer Rec Tech Ltd |
DNA-PK inhibitors
|
|
GB0119863D0
(en)
|
2001-08-14 |
2001-10-10 |
Cancer Res Campaign Tech |
DNA-PK inhibitors
|
|
GB0119865D0
(en)
|
2001-08-14 |
2001-10-10 |
Cancer Res Campaign Tech |
DNA-PK inhibitors
|
|
CN1551766A
(zh)
*
|
2001-09-05 |
2004-12-01 |
������������ʽ���� |
淋巴细胞活化抑制剂和自身免疫性疾病治疗剂
|
|
US7049313B2
(en)
|
2002-02-25 |
2006-05-23 |
Kudos Pharmaceuticals Ltd. |
ATM inhibitors
|
|
EP2311818B1
(en)
*
|
2002-02-28 |
2013-01-16 |
Novartis AG |
Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
|
|
AR038703A1
(es)
|
2002-02-28 |
2005-01-26 |
Novartis Ag |
Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
|
|
CA2495661C
(en)
*
|
2002-08-16 |
2011-06-14 |
Kinacia Pty Ltd. |
Inhibition of phosphoinositide 3-kinase beta
|
|
CN101260104A
(zh)
*
|
2002-08-16 |
2008-09-10 |
阿斯利康(瑞典)有限公司 |
抑制磷酸肌醇3-激酶β
|
|
CA2494700C
(en)
|
2002-08-26 |
2011-06-28 |
Takeda Pharmaceutical Company Limited |
Calcium receptor modulating compound and use thereof
|
|
WO2004052373A1
(en)
*
|
2002-12-06 |
2004-06-24 |
Warner-Lambert Company Llc |
Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
|
|
GB0305152D0
(en)
|
2003-03-06 |
2003-04-09 |
Novartis Ag |
Organic compounds
|
|
JP2006522124A
(ja)
*
|
2003-04-03 |
2006-09-28 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
プロテインキナーゼのインヒビターとして有用な組成物
|
|
KR20070087266A
(ko)
|
2003-04-03 |
2007-08-28 |
세마포르 파머슈티컬즈, 아이엔씨. |
피아이-3 키나아제 억제제 프로드러그
|
|
ATE365735T1
(de)
*
|
2003-06-05 |
2007-07-15 |
Warner Lambert Co |
Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel
|
|
US20040259926A1
(en)
*
|
2003-06-05 |
2004-12-23 |
Bruendl Michelle M. |
3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
|
|
BRPI0411098A
(pt)
*
|
2003-06-05 |
2006-07-18 |
Warner Lambert Co |
benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos
|
|
US7429660B2
(en)
|
2003-08-13 |
2008-09-30 |
Kudos Pharmaceuticals Limited |
ATM inhibitors
|
|
MXPA06002513A
(es)
*
|
2003-09-04 |
2006-06-20 |
Warner Lambert Co |
Benzo[b]tiofenos halo-sustituidos con actividad inhibidora de fosfoinositido-3-cinasas (pi3k) como agentes terapeuticos.
|
|
ES2285517T3
(es)
*
|
2003-10-31 |
2007-11-16 |
Warner-Lambert Company Llc |
Pirimidinas como inhibidores de fosfoinositida-3-cinasas(pi3k).
|
|
CA2554551A1
(en)
*
|
2004-01-26 |
2005-10-13 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
|
WO2005113556A1
(en)
|
2004-05-13 |
2005-12-01 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
|
CN1300163C
(zh)
*
|
2004-06-23 |
2007-02-14 |
南京大学 |
3－羟基色原酮糖苷及其制法和用途
|
|
UA88329C2
(en)
|
2004-09-20 |
2009-10-12 |
Кудос Фармасьютикалз Лимитед |
Dna-pk inhibitors
|
|
CN101115747A
(zh)
|
2005-02-09 |
2008-01-30 |
库多斯药物有限公司 |
Atm抑制剂
|
|
AR053358A1
(es)
|
2005-04-15 |
2007-05-02 |
Cancer Rec Tech Ltd |
Inhibidores de adn - pk
|
|
WO2007127366A2
(en)
|
2006-04-25 |
2007-11-08 |
Targegen, Inc. |
Kinase inhibitors and methods of use thereof
|
|
ES2474865T3
(es)
*
|
2006-06-22 |
2014-07-09 |
Prana Biotechnology Limited |
Método de tratamiento de un tumor cerebral glioma
|
|
EP2124948B1
(en)
*
|
2007-02-21 |
2017-07-26 |
NC bit, Inc. |
Compositions for treating hyperproliferative vascular disorders and cancers
|
|
EP2157092A4
(en)
|
2007-04-11 |
2011-04-13 |
Ajinomoto Kk |
Remedy for diabetes
|
|
JP2010529031A
(ja)
*
|
2007-05-29 |
2010-08-26 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体
|
|
EP2170338A2
(en)
*
|
2007-07-06 |
2010-04-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dna-pkcs modulates energy regulation and brain function
|
|
RU2010133715A
(ru)
*
|
2008-01-25 |
2012-02-27 |
Астразенека Аб (Se) |
ЭНАНТИОМЕРНО ЧИСТАЯ (-)2-[1-(7-МЕТИЛ-2-(МОРФОЛИН-4-ИЛ)-4-ОКСО-4Н-ПИРИДО[1,2-a]ПИРИМИДИН-9-ИЛ)БЕНЗОЙНАЯ КИСЛОТА, ЕЕ ПРИМЕНЕНИЕ В ФАРМАКОТЕРАПИИ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЕЕ
|
|
JP2011518174A
(ja)
*
|
2008-04-18 |
2011-06-23 |
シェノゲン ファーマ グループ リミテッド |
エストロゲン受容体に関連する疾患を処置するための化合物及び方法
|
|
WO2010037129A1
(en)
|
2008-09-29 |
2010-04-01 |
Sirtris Pharmaceuticals Inc. |
Quinazolinone, quinolone and related analogs as sirtuin modulators
|
|
US8110578B2
(en)
*
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
|
JP5794919B2
(ja)
|
2008-11-13 |
2015-10-14 |
ギリアード カリストガ エルエルシー |
血液学的な悪性疾患のための療法
|
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
|
WO2011001115A1
(fr)
|
2009-07-02 |
2011-01-06 |
Sanofi-Aventis |
Nouveaux derives de 6-morpholin-4-yl-pyrimidin-4- ( 3h ) -one, leur preparation pharmaceutique comme inhibiteurs de phos phorylat i on d ' akt ( pkb )
|
|
NZ597579A
(en)
|
2009-07-02 |
2013-06-28 |
Sanofi Sa |
Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
|
|
LT2448939T
(lt)
|
2009-07-02 |
2017-06-12 |
Sanofi |
2,3-dihidro-1h-imidazo {1,2-a} pirimidin-5-ono dariniai, jų gamyba ir farmacinis panaudojimas
|
|
BRPI1015943A8
(pt)
|
2009-07-02 |
2018-01-09 |
Sanofi Sa |
derivados de 1,2,3,4-tetra - hidro - pirimido {1,2-a} pirimidin-6-ona, o respectivo preparo e a respectiva utilização farmacêutica.
|
|
WO2011011550A1
(en)
|
2009-07-21 |
2011-01-27 |
Calistoga Pharmaceuticals Inc. |
Treatment of liver disorders with pi3k inhibitors
|
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
|
IT1403156B1
(it)
*
|
2010-12-01 |
2013-10-04 |
Università Degli Studi Di Torino |
Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi.
|
|
HUE024504T2
(en)
|
2010-12-23 |
2016-01-28 |
Sanofi Sa |
Pyrimidine derivatives, a process for their preparation and their use in medicine
|
|
FR2969613B1
(fr)
*
|
2010-12-23 |
2013-02-08 |
Sanofi Aventis |
Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique
|
|
FR2969612B1
(fr)
*
|
2010-12-23 |
2013-02-08 |
Sanofi Aventis |
Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
|
|
WO2012089633A1
(fr)
|
2010-12-28 |
2012-07-05 |
Sanofi |
Nouveaux derives de pyrimidines, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
|
|
WO2013111850A1
(ja)
|
2012-01-26 |
2013-08-01 |
第一三共株式会社 |
骨形成促進作用を有するクロモン誘導体
|
|
EP2812004B1
(en)
*
|
2012-02-10 |
2018-06-27 |
PTC Therapeutics, Inc. |
Compounds for treating spinal muscular atrophy
|
|
BR112014021531B1
(pt)
|
2012-03-01 |
2022-10-04 |
Ptc Therapeutics, Inc. |
Composto, composição farmacêutica e usos dos mesmos
|
|
EA201691327A1
(ru)
|
2012-03-05 |
2017-03-31 |
Джилид Калистога Ллс |
Полиморфные формы (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
|
|
CN104470909B
(zh)
|
2012-03-23 |
2018-04-24 |
Ptc医疗公司 |
用于治疗脊髓性肌萎缩的化合物
|
|
ITMI20120514A1
(it)
*
|
2012-03-29 |
2013-09-30 |
Cnr Consiglio Naz Delle Ric Erche |
Agente terapeutico per il trattamento dei vasi sanguigni
|
|
FR2992314B1
(fr)
|
2012-06-22 |
2015-10-16 |
Sanofi Sa |
Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
|
|
US10195202B2
(en)
|
2013-12-19 |
2019-02-05 |
Ptc Therapeutics, Inc. |
Methods for modulating the amount of RNA transcripts
|
|
AU2014364414A1
(en)
|
2013-12-20 |
2016-06-30 |
Gilead Calistoga Llc |
Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one
|
|
CN105849108A
(zh)
|
2013-12-20 |
2016-08-10 |
吉利德卡利斯托加公司 |
磷脂酰肌醇3-激酶抑制剂的制备方法
|
|
CN106459005A
(zh)
|
2014-06-13 |
2017-02-22 |
吉利德科学公司 |
磷脂酰肌醇3‑激酶抑制剂
|
|
EP3298017B1
(en)
*
|
2015-05-20 |
2019-08-14 |
H. Hoffnabb-La Roche Ag |
Compounds for treating spinal muscular atrophy
|
|
EP3310169B1
(en)
|
2015-05-30 |
2023-05-17 |
PTC Therapeutics, Inc. |
Methods for modulating rna splicing
|
|
CN108697709A
(zh)
|
2015-12-10 |
2018-10-23 |
Ptc医疗公司 |
用于治疗亨廷顿病的方法
|
|
US10646465B2
(en)
|
2015-12-17 |
2020-05-12 |
Biokine Therapeutics Ltd. |
Small molecules against cancer
|
|
JP6941611B2
(ja)
*
|
2015-12-17 |
2021-09-29 |
バイオカイン セラピューティックス リミテッド |
ケモカイン活性および／または癌細胞成長を阻害するための小分子
|
|
EP3496724B8
(en)
|
2016-08-12 |
2021-11-17 |
Madera Therapeutics, LLC |
Protein kinase regulators
|
|
AU2017363369A1
(en)
|
2016-11-28 |
2019-05-30 |
Ptc Therapeutics, Inc |
Methods for modulating RNA splicing
|
|
JP2020506904A
(ja)
|
2017-01-27 |
2020-03-05 |
シグナルアールエックス ファーマシューティカルズ，インコーポレイテッド |
キナーゼ、ブロモドメイン及びチェックポイント阻害剤としてのチエノピラノン及びフラノピラノン
|
|
AU2018282154B2
(en)
|
2017-06-05 |
2022-04-07 |
Ptc Therapeutics, Inc. |
Compounds for treating huntington's disease
|
|
US11608501B2
(en)
|
2017-06-14 |
2023-03-21 |
Ptc Therapeutics, Inc. |
Methods for modifying RNA splicing
|
|
CN111182898B
(zh)
|
2017-06-28 |
2024-04-16 |
Ptc医疗公司 |
用于治疗亨廷顿氏病的方法
|
|
WO2019005993A1
(en)
|
2017-06-28 |
2019-01-03 |
Ptc Therapeutics, Inc. |
METHODS OF TREATING HUNTINGTON'S DISEASE
|
|
BR112020019373A2
(pt)
|
2018-03-27 |
2020-12-29 |
Ptc Therapeutics, Inc. |
Compostos para o tratamento da doença de hutington
|
|
EP3814360B8
(en)
|
2018-06-27 |
2024-11-06 |
PTC Therapeutics, Inc. |
Heteroaryl compounds for treating huntington's disease
|
|
IL279688B2
(en)
|
2018-06-27 |
2025-01-01 |
Ptc Therapeutics Inc |
Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
|
|
WO2020005877A1
(en)
|
2018-06-27 |
2020-01-02 |
Ptc Therapeutics, Inc. |
Heteroaryl compounds for treating huntington's disease
|
|
CN109748914B
(zh)
*
|
2018-12-29 |
2021-05-25 |
上海珂臻医药科技有限公司 |
吡啶并嘧啶类化合物及其应用
|
|
EP4524131A1
(en)
|
2019-05-15 |
2025-03-19 |
AlonBio Ltd. |
Small molecules for treating cancer, inhabiting chemokine activity and/or inducing cell death
|
|
AR121719A1
(es)
|
2020-04-03 |
2022-06-29 |
Petra Pharma Corp |
Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
|
|
CN111533721B
(zh)
*
|
2020-05-15 |
2022-04-26 |
浙江大学 |
苯并吡喃酮或喹啉酮类化合物及其应用
|
|
WO2021247859A1
(en)
*
|
2020-06-03 |
2021-12-09 |
Yumanity Therapeutics, Inc. |
Pyridopyrimidines and methods of their use
|
|
IL304895A
(en)
*
|
2021-02-01 |
2023-10-01 |
Geode Therapeutics Inc |
INHIBITORS OF PHOSPHOINOSITIDE 3 KINASE BETA Preparations containing them and their use for treatment
|
|
MX2023013080A
(es)
|
2021-05-03 |
2023-11-16 |
Petra Pharma Corp |
Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades.
|
|
WO2022251482A1
(en)
|
2021-05-27 |
2022-12-01 |
Petra Pharma Corporation |
Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer
|
|
TW202329930A
(zh)
|
2021-09-30 |
2023-08-01 |
美商佩特拉製藥公司 |
用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
|
|
CA3232906A1
(en)
*
|
2021-10-07 |
2023-04-13 |
Alessandro Boezio |
Pi3k-alpha inhibitors and methods of use thereof
|
|
WO2025136936A1
(en)
*
|
2023-12-19 |
2025-06-26 |
Merck Sharp & Dohme Llc |
Agonists of trem2 activity
|